Current perspectives in dissolution testing of conventional and novel dosage forms

International Journal of Pharmaceutics

Volumn 328, Issue 1 SPEC. ISS., 2007, Pages 12-21

  Azarmi, Shirzad ^a,b   Roa, Wilson ^a   Löbenberg, Raimar ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Aerosols; Buccal sublingual tablets; Chewable tablets; Chewing gums; Conventional dosage forms; Dissolution testing; Extended release; Immediate release tablets; Novel dosage forms; Powders; Semisolids; Soft gelatin capsules; Suppositories; Transdermal patches; USP

Indexed keywords

ACETYLSALICYLIC ACID; ALBENDAZOLE; ALPHA TOCOPHEROL NICOTINATE; AMFEBUTAMONE; AMPICILLIN; BETAXOLOL; BROMPHENIRAMINE; CARBAMAZEPINE; CEFACLOR; CEFADROXIL; CHEMICAL COMPOUND; DIHYDROERGOTOXINE MESILATE; DME 50733; ERGOTAMINE TARTRATE; ETHAMBUTOL; GLIBENCLAMIDE; GLUCOCORTICOID; HYDROCORTISONE SODIUM SUCCINATE; INDOMETACIN; ISOSORBIDE DINITRATE; LITHIUM CARBONATE; NICOTINE; NIFEDIPINE; PARACETAMOL; PHENYLPROPANOLAMINE; PSEUDOEPHEDRINE; SB 247083; TRITON X 100; TYLOXAPOL; UNINDEXED DRUG; VINPOCETINE;

AEROSOL; CHEWABLE TABLET; CHEWING GUM; CONTROLLED DRUG RELEASE; CREAM; DISSOLUTION; DRUG CAPSULE; DRUG DOSAGE FORM; DRUG RELEASE; DRUG SOLUBILITY; GEL; INTESTINE FLUID; METHODOLOGY; MOUTH CAVITY; OINTMENT; POWDER; PRIORITY JOURNAL; REVIEW; STOMACH JUICE; SUPPOSITORY; SUSTAINED RELEASE FORMULATION; TABLET FORMULATION; TRANSDERMAL PATCH;

EID: 34547651036     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2006.10.001     Document Type: Review

References (84)

1. Abdelbary G., Eouani C., Prinderre P., Joachim J., Renier J., and Piccerelle P. Determination of the in vitro disintegration profile of rapidly disintegrating tablets and correlation with oral disintegration. Int. J. Pharm. 292 (2005) 29-41
2. Aiache J.M., Aoyagi N., Blume H., Dressman J., Friedel H.B., and Grady I.T. FIP guidelines for dissolution testing of solid oral products. Dissolution Technol. 4 (1997) 5-13
3. Akbari J., Nokhodchi A., Farid D., Adrangui M., Siahi-Shadbad M.R., and Saeedi M. Development and evaluation of buccoadhesive propranolol hydrochloride tablet formulations: effect of fillers. Farmacology 59 (2004) 155-161
4. Ansoborlo E., Henge-Napoli M.H., Chazel V., Gilbert R., and Guilmette R.A. Review and critical analysis of available in vitro dissolution tests. Health Phys. 77 (1999) 638-645
5. Babu R.J., and Pandit J.K. Effect of penetration enhancers on the release and skin permeation of bupranolol from reservoir-type transdermal delivery systems. Int. J. Pharm. 288 (2005) 325-334
6. Ceschel G.C., Maffei P., Borgia S.L., and Ronchi C. Design and evaluation of buccal adhesive hydrocortisone acetate (HCA) tablets. Drug Deliv. 8 (2001) 161-171
7. Chatterjee A., Moulik S.P., Majhi P.R., and Sanyal S.K. Studies on surfactant-biopolymer interaction. I. Microcalorimetric investigation on the interaction of cetyltrimethylammonium bromide (CTAB) and sodium dodecylsulfate (SDS) with gelatin (Gn), lysozyme (Lz) and deoxyribonucleic acid (DNA). Biophys. Chem. 98 (2002) 313-327
8. Chauhan B., Shimpi S., and Paradkar A. Preparation and characterization of etoricoxib solid dispersions using lipid carriers by spray drying technique. AAPS Pharm. Sci. Technol. 6 (2005) 48-55
9. Cilurzo F., Minghetti P., Selmin F., Casiraghi A., and Montanari L. Polymethacrylate salts as new low-swellable mucoadhesive materials. J. Control. Release 88 (2003) 43-53
10. Crison J.R., Weiner N.D., and Amidon G.L. Dissolution media for in vitro testing of water soluble drugs: effect of surfactant purity on in vitro dissolution of carbamazepine in aqueous solutions of sodium lauryl sulfate. J. Pharm. Sci. 87 (1997) 384-388
11. Csoka I., Csanyi E., Zapantis G., Nagy E., and Eros I. In vitro and in vivo percutaneous absorption of topical dosage forms: case studies. Int. J. Pharm. 291 (2005) 11-19
12. Davies N.M., and Feddah M.I. A novel method for assessing dissolution of aerosol inhaler products. Int. J. Pharm. 255 (2003) 175-187
13. Davis R.E., Hartman C.W., and Fincher J.H. Dialysis of ephedrine and pentobarbital from whole human saliva and simulated saliva. J. Pharm. Sci. 60 (1971) 429-432
14. Dennis N.A., Blauer H.M., and Kent J.E. Dissolution fractions and half-times of single source yerllowcake in simulated lung fluids. Health Phys. 42 (1982) 469-477
15. Dinora G.E., Julio R., Nelly C., Lilian Y.M., and Cook H.J. In vitro characterization of some biopharmaceutical properties of praziquantel. Int. J. Pharm. 295 (2005) 93-99
16. Dor P.J.M., and Fix J.A. In vitro determination of disintegration time of quick dissolving tablets using a new method. Pharm. Dev. Technol. 5 (2000) 575-577
17. Eidson A.F. Biological Characterization of Radiation Exposure and Dose Estimates for Inhaled Uranium Milling Effluents (1982), US Nuclear Regulatory Commission, Washington, DC NUREG/CR-2539, LMF-94
18. Eidson A.F., and Mehinney J.A. In Vitro Dissolution of Respirable Aerosols of Industrial Uranium and Plutonium Mixed-Oxide Nuclear Fuels (1981), US Nuclear Regulatory Commission, Washington, DC NUREG/CR-2171, LMF-79
19. ElGindy G.A. Formulation development and in-vivo evaluation of buccoadhesive tablets of verapamil hydrochloride. Bull. Pharm. Sci. 27 (2004) 293-306
20. European Pharmacopoeia 4th Edition, 2002. General Chapter 2.9.25. Chewing Gum, Medicated, Drug Release From. Directorate for the Quality of Medicines of the Council of Europe, Strasbourg, France, pp. 227-228.
21. Fabregas J.L., and Garcia N. In vitro studies on buccoadhesive tablet formulations of hydrocortisone hemisuccinate. Drug Dev. Ind. Pharm. 21 (1995) 1689-1696
22. Galia E., Nicolaides E., Horter D., Lobenberg R., Reppas C., and Dressman J.B. Evaluation of various dissolution media for predicting in vivo performance of class I and II drugs. Pharm. Res. 15 (1998) 698-705
23. Gamble J.L. Chemical Anatomy, Physiology and Pathology of Extracelluar Fluid (1967), Harvard University Press, Boston
24. Gautam J., and Schott H. Interaction of anionic compounds with gelatin. I. Binding studies. J. Pharm. Sci. 83 (1994) 922-930
25. Gupta S.P., and Jain S.K. Development of matrix-membrane transdermal drug delivery system for atenolol. Drug Deliv. 11 (2004) 281-286
26. Hao J., and Heng P.W.S. Buccal delivery systems. Drug Dev. Ind. Pharm. 29 (2003) 821-832
27. Hurtado y de la Pena M., Vargas Alvarado Y., Dominguez-Ramirez A.M., and Cortes Arroyo A.R. Comparison of dissolution profiles for albendazole tablets using USP apparatus 2 and 4. Drug Dev. Ind. Pharm. 29 (2003) 777-784
28. Hu J., Kyad A., Ku V., Zhou P., and Cauchon N. A comparison of dissolution testing on lipid soft gelatin capsules using USP apparatus 2 and apparatus 4. Dissolution Technol. May (2005) 6-9
29. Hughes L. Tightening up buccal testing. Manuf. Chem. 74 (2003) 28-30
30. Ikinci G., Senel S., Wilson C.G., and Sumnu M. Development of a buccal bioadhesive nicotine tablet formulation for smoking cessation. Int. J. Pharm. 277 (2004) 173-178
31. Jain A.C., Aungst B.J., and Adeyeye M.C. Development and in vivo evaluation of buccal tablets prepared using danazol-sulfobutylether 7 beta-cyclodextrin (SBE 7) complexes. J. Pharm. Sci. 91 (2002) 1659-1668
32. Janicki S., Sanitowska M., Zebrowska W., Gabiga H., and Kupiec M. Evaluation of paracetamol suppositories by a pharmacopoeial dissolution test-commets on methodology. Eur. J. Pharm. Biopharm. 20 (2001) 249-254
33. Jinno J., Oh D.M., Crison J.R., and Amidon G.L. Dissolution of ionizable water insoluble drugs: combined effect of pH and surfactant. J. Pharm. Sci. 89 (2000) 268-274
34. Jug M., and BecirevicLacan M. Influence of hydroxypropyl-beta-cyclodextrin complexation on piroxicam release from buccoadhesive tablets. Eur. J. Pharm. Sci. 21 (2004) 251-260
35. Jun S.W., Kim M.S., Jo G.H., Lee S., Woo J.S., Park J.S., and Hwang S.J. Cefuroxime axetil solid dispersions prepared using solution enhanced dispersion by supercritical fluids. J. Pharm. Pharmacol. 57 (2005) 1529-1537
36. Löbenberg R., and Amidon G.L. Modern bioavailability, bioequivalence and biopharmaceutics classification system: new scientific approaches to International Regulatory Standards. Eur. J. Pharm. Biopharm. 50 (2000) 3-12
37. Löbenberg R., Kramer J., Shah V.P., Amidon G.L., and Dressman J.B. Dissolution testing as a prognostic tool for oral drug absorption: dissolution behavior of glibenclamide. Pharm. Res. 17 (2000) 439-444
38. Mafune E., Takahashi M., and Takasugi N. In vivo and in vitro evaluations of water-absorption properties of various ointments. Drug Dev. Ind. Pharm. 24 (1998) 51-56
39. Maggin L., Segale L., Conti S., Machiste E.O., Salini A., and Conte U. Preparation and evaluation of release characteristics of 3 TabGum, a novel chewing device. Eur. J. Pharm. Sci. 24 (2005) 487-493
40. Maulik S., Dutta P., Chattoraj D.K., and Moulik S.P. Biopolymer-surfactant interactions. 5. Equilibrium studies on the binding of cetyltrimethyl ammonium bromide and sodium dodecyl sulfate with bovine serum albumin, beta-lactoglobulin, hemoglobin, gelatin, lysozyme and deoxyribonucleic acid. Colloids Surf. B Biointerfaces 11 (1998) 1-8
41. Missel P.J., Stevens L.E., and Mauger J.W. Dissolution of anecortave acetate in a cylindrical flow cell: re-evaluation of convective diffusion/drug dissolution for sparingly soluble drugs. Pharm. Dev. Technol. 9 (2004) 453-459
42. Mohammed F.A., and Khedr H. Preparation and in vitro/in vivo evaluation of the buccal bioadhesive properties of slow-release tablets containing miconazole nitrate. Drug Dev. Ind. Pharm. 29 (2003) 321-337
43. Moller H. Dissolution testing of different dosage forms using the flow through method. Pharm. Ind. 45 (1983) 617-622
44. Mu X., Tobyn M.J., and Staniforth J.N. Development and evaluation of bio-dissolution systems capable of detecting the food effect on a polysaccharide-based matrix system. J. Control. Release 93 (2003) 309-318
45. Mumtaz A.M., and Ch'ng H.S. Design of a dissolution apparatus suitable for in situ release study of triamcinolone acetonide from bioadhesive buccal tablets. Int. J. Pharm. 121 (1995) 129-139
46. Neisingh S.E., Sam A.P., and de Nijs H. Dissolution method for hard and soft gelatin capsules containing testosterone undecanoate in oleic acid. Drug Dev. Ind. Pharm. 12 (1986) 651-663
47. Nicolaides E., Galia E., Efthymiopoulos C., Dressman J.B., and Reppas C. Forecasting the in vivo performance of four low solubility drugs from their in vitro dissolution data. Pharm. Res. 16 (1999) 1876-1882
48. Parodi B., Russo E., Caviglioli G., Cafaggi S., and Bignardi G. Development and characterization of a buccoadhesive dosage form of oxycodone hydrochloride. Drug Dev. Ind. Pharm. 22 (1996) 445-450
49. Perng C.Y., Kearney A.S., Palepu N.R., Smith B.R., and Azzarano L.M. Assessment of oral bioavailability enhancing approaches for SB-247083 using flow-through cell dissolution testing as one of the screens. Int. J. Pharm. 250 (2003) 147-156
50. Pharmacopeial Forum, 2005, USP, 31, 5, General Chapter 〈1092〉. The Dissolution Procedure: Development and Validation. pp. 1463-1475
51. Pillay V., and Fassihi R. A new method for dissolution studies of lipid-filled capsules employing nifedipine as a model drug. Pharm. Res. 16 (1999) 333-337
52. Rades T., Schutze W., and Muller-Goymann C.C. Interactions between gelatin and amphiphilic substances. Pharmazie 48 (1993) 425-432
53. Rambali B., Baert L., Jans E., and Massart D.L. Influence of the roll compactor parameter settings and the compression pressure on the buccal bioadhesive tablet properties. Int. J. Pharm. 220 (2001) 129-140
54. Rao K.P., Chawla G., Kaushal A.M., and Bansal A.K. Impact of solid-state properties on lubrication efficacy of magnesium stearate. Pharm. Dev. Technol. 10 (2005) 423-437
55. Ribeiro L., Ferreira D.C., and Veiga F.J.B. In vitro controlled release of vinpocetine-cyclodextrin-tartaric acid multicomponent complexes from HPMC swellable tablets. J. Control. Release 103 (2005) 325-339
56. Rohrs B.R., Burch-Clark D.L., Witt M.J., and Stelzer D.J. USP dissolution apparatus 3 (reciprocating cylinder): instrument parameter effects on drug release from sustained release formulations. J. Pharm. Sci. 84 (1995) 922-926
57. Sanghvi P.P., and Collins C.C. Comparison of diffusion studies of hydrocortisone between the Franz cell and the enhancer cell. Drug Dev. Ind. Pharm. 19 (1993) 1573-1585
58. Schamp K., Schreder S.A., and Dressman J. Development of an in vitro/in vivo correlation for lipid formulations of EMD 50733, a poorly soluble, lipophilic drug substance. Eur. J. Pharm. Biopharm. 62 (2006) 227-234
59. Schulte-Lobbert S., Westerhoff K., Wilke A., Schubert-Zsilavecz M., and Wurglics M. Development of a high-performance-liquid-chromatographic method for the determination of biapigenin in biorelevant media. J. Pharm. Biomed. Anal. 33 (2003) 53-60
60. Senel S., Kremer M., Nagy K., and Squier C. Delivery of bioactive peptides and proteins across oral (Buccal) mucosa. Curr. Pharm. Biotechnol. 2 (2001) 175-186
61. Serajuddin A.T.M., Sheen P.C., Mufson D., Bernstein D.F., and Augustine M.A. Effect of vehicle amphiphilicity on the dissolution and bioavailability of a poorly water soluble drug from solid dispersions. J. Pharm. Sci. 77 (1998) 414-417
62. Shah V.P., Tymes N.W., and Skelly J.P. In vitro release profile of clonidine transdermal therapeutic systems and scopolamine patches. Pharm. Res. 6 (1989) 346-351
63. Shah N.H., Carjaval M.T., Patel C.I., Infeld M.H., and Malick A.W. Self-emulsifying drug delivery systems (SEDDS) for improving in vitro dissolution and oral absorption of lipophilic drugs. Bull. Tech. Gattefosse 85 (1992-1993) 45-54
64. Shay L.R., Irwin W.J., Grattan T.J., and Conway B.R. The development of modified dissolution method suitable for investigating powder mixtures. Drug Dev. Ind. Pharm. 28 (2002) 1147-1153
65. Sheen P.C., Kim S.I., Petillo J.J., and Serajuddin A.T.M. Bioavailability of a poorly water soluble drug from tablet and solid dispersion in humans. J. Pharm. Sci. 80 (1991) 712-714
66. Shimpi S.L., Chauhan B., Mahadik K.R., and Paradkar A. Stabilization and improved in vivo performance of amorphous etoricoxib using Gelucire 50/13. Pharm. Res. 22 (2005) 1727-1734
67. Siewert M., Dressman J., Brown C., Shah V., and Williams R. FIP/AAPS guidelines for dissolution/in vitro release testing of novel/special dosage forms. Dissolution Technol. 10 (2003) 10-13 15
68. Takahashi M., Mochizuki M., Wada K., Itoh T., Ohta M., and Goto M. Studies on dissolution tests of soft gelatin capsules. V. Rotating dialysis cell method. Chem. Pharm. Bull. 42 (1994) 1672-1675
69. Tavss E.A., Gaffar A., and King W.J. Studies on the formation of electrostatic complexes between benzethonium chloride and anionic polymers. J. Pharm. Sci. 73 (1984) 1148-1152
70. Thakker Kailas D., and Chern Wendy H. Development and validation of in vitro release tests for semisolid dosage form-case study. Dissolution Technol. (2003 (May)) 10-15
71. Tirnaksiz F., and Yuce Z. Development of transdermal system containing nicotine by using sustained release dosage design. Farmacology 60 (2005) 763-770
72. Tugcu-Demiroz F., Acarturk F., Takka S., and Konus-Boyunaga O. In-vitro and in-vivo evaluation of mesalazine-guar gum matrix tablets for colonic drug delivery. J. Drug Target. 12 (2004) 105-112
73. Ueda C.T., Shah V.P., Derdzinski K., Ewing G., Flynn G., Maibach H., Marques M., Shaw S., Thakker K., and Yaccobi A. Performance test for topical and transdermal dosage form. Pharmacopeial Forum 32 (2006) 1586-1589
74. United States Pharmacopeia 28, 〈724〉 Drug Release, pp. 2415-2420.
75. Valizadeh H., Nokhodchi A., Qarakhani N., Zakeri-Milani P., Azarmi S., Hassanzadeh D., and Löbenberg R. Physicochemical characterization of solid dispersions of indomethacin with PEG 6000, Myrj 52, Lactose, sorbitol, dextrin, and Eudragit E100. Drug Dev. Ind. Pharm. 30 (2004) 303-317
76. Van Amerongen I.A., De Ronde H.A.G., and Klooster N.T.M. Physical-chemical characterization of semisolid topical dosage form using a new dissolution system. Int. J. Pharm. 86 (1992) 9-15
77. Van Buskirk G.A., Gonzalez M.A., Shah V.P., Barnhardt S., Barrett C., and Berge S. Scale up of adhesive transdermal drug delivery systems. Pharm. Res. 14 (1997) 848-852
78. Vankel Technology Group Buyer's Guide, 2005. p. 37.
79. Von Orelli J., and Leuenberger H. Search for technological reasons to develop a capsule or a tablet formulation with respect to wettability and dissolution. Int. J. Pharm. 287 (2004) 135-145
80. Wei H., and Löbenberg R. Biorelevant dissolution media as a predictive tool for glyburide a class II drug. Eur. J. Pharm. Sci. 29 1 (2006) 45-52
81. Williams R.L., and Foster T.S. Dissolution: a continuing perspective. Dissolution Technol. August (2004) 6-14
82. Williams A.C., Timmins P., Lu M.C., and Forbes R.T. Disorder and dissolution enhancement: deposition of ibuprofen on to insoluble polymers. Eur. J. Pharm. Sci. 26 (2005) 288-294
83. Wong D., Larrabee S., Clifford K., Tremblay J., and Friend D.R. USP Dissolution Apparatus III (reciprocating cylinder) for screening of guar based colonic delivery formulations. J. Control. Release 47 (1997) 173-179
84. Young C.R., Dietzsch C., and McGinity J.W. Compression of controlled-release pellets produced by a hot-melt extrusion and spheronization process. Pharm. Dev. Technol. 10 (2005) 133-139